We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Kanabo Group Plc | LSE:KNB | London | Ordinary Share | GB00BYQCS703 | ORD 2.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.95 | 0.90 | 1.20 | - | 0.00 | 07:30:26 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 895k | -7.99M | -0.0126 | -0.75 | 6.01M |
Date | Subject | Author | Discuss |
---|---|---|---|
06/1/2025 08:49 | Kanabo Group plc (LSE: KNB), a health tech company with digital health services and specialist medicines, announces that Mr David Tsur will be stepping down from the Board of Directors with effect from 30 January 2025. Mr Tsur has served as a member of the Board since Admission in early 2021 and held the position of Chairman for more than 2 years. He has been part of the Kanabo journey since 2018. | currypasty | |
06/12/2024 12:48 | What a reference; equal parts observant and hilarious. We unfortunately have no option but to hope the CE mark comes in before the ever decreasing spiral sees KNB hitting the deck | 1chrism | |
03/12/2024 18:25 | I'm beginning to think this share has turned into an oozlum bird | bobea | |
13/11/2024 15:18 | all seems to have gone downhill from then free stock charts from uk.advfn.com | currypasty | |
13/11/2024 14:19 | Alas, it is from 2021. | 1chrism | |
12/11/2024 14:37 | hxxps://freetrade.io | endocan | |
04/11/2024 18:04 | I'm not here to argue or wind people up but Kanabo paid 13.5 million for the GP service in 2022 and spent money improving it. Also they have opened walk-in clinics and various potential revenue streams. So how is all of this now worth 6.7 million?, it is obviously not a true valuation but one they will have to use if they stay listed. Oxford cannabinoid market cap was 1 million before delist but just one of there projects was independently valued at 27 million. | bobea | |
04/11/2024 17:47 | I realise that they are not the same type of company but the point is both companies share price has collapsed.Yes Kanabo have increased revenue but are still running at a loss, so unless something dramatically changes fairly soon they will need more money. At this price will not do holders any good. I believe Kanabo floated at about 6p and is now less than 1p. I honestly believe the only way is to delist and get private funding on true value not value based on share price. | bobea | |
04/11/2024 17:10 | For those new to Kanabo, it is worth noting that aside from both companies working with cannabis, Oxford Cannabinoid and Kanabo exist in two entirely unique markets.Oxford focuses on the creation of prescription based medicine, Kanabo is in the wellness space. Oxford's science is geared to drug trials and Kanabo is focussed on their vape technology getting a CE mark. It is understandable to be confused by the remit of cannabis companies but the reason for Oxford's problems are entirely separate from Kanabo.And on the latter, it is quite simply that Kanabo await approval for their vape pen's CE mark. The timescale for this is the only potential crisis point. As revenue has been increasing (+50+%) at last report, the potential that a fundraise will be required will likely be apparent in next report. | 1chrism | |
04/11/2024 15:15 | With a market cap of £6.7 million any placing at these prices will wipe out existing holders, remember people's reaction when they raised at 15p.Kanabo will have to raise funds eventually I think the only way is to do what Oxford cannabinoid did and delist then hopefully come back when in a stronger position. | bobea | |
30/10/2024 16:11 | Kanabo Group’s Chairperson, Ian Mattioli, has transferred his entire holding of 17,361,111 ordinary shares to his daughter, without any financial consideration. This transaction maintains his beneficial interest in the shares at 2.75% of the company’s total issued capital. The move highlights a significant internal transfer within the leading health tech company, attracting attention from investors interested in stock movements. | chica1 | |
23/10/2024 07:09 | KNB have a £700k stake in HELD. However, their is a significant difference to the other cannibis companies you mention. KNB are farm to pharmacy with expanding revenue. What holds the company back is the wait for CE mark approval of their vape pen. | 1chrism | |
22/10/2024 21:18 | I believe KNB had a stake in HELD who's shares were suspended after a crash in share price.🤔 | bobea | |
22/10/2024 20:59 | Thought this company was different to cbx and mgc but it will probably do the same and change its name and wipe out existing share holders.maybe this was the plan all along either way it's not coming back from this. | bobea | |
09/10/2024 16:45 | a bit of a sell off today, no idea why | currypasty | |
27/8/2024 14:26 | How can the ceo justify his salary when the shares are in the doldrums, Elon Musk you are not,Spend more time growing the company than counting your proceeds | gist328 | |
27/8/2024 10:48 | Pump on the way.. Might be a capital raise.. Who knows🙄ԅ | chica1 | |
21/8/2024 15:56 | Maybe the CE mark application is about to be shelved? | 1chrism | |
21/8/2024 15:31 | 600k sell ! | currypasty | |
31/7/2024 14:10 | On the road to ZERO unless management does something quickly. Have some free shares because of a topslice. Doesn't help to be associated with Hellenic Dynamics.HELD's management should all be jailed for fraud. | chica1 | |
18/7/2024 15:03 | looking a bit sick, wasnt much in the agm | currypasty |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions